This study was designed to evaluate whether the administration of commensal Shewanella sp. MR-7 (MR-7) could ameliorate lipopolysaccharide (LPS)-induced intestine dysfunction in turbot. Fish (body weight: 70.00 ± 2.00 g) were randomly divided into three groups including the control group treated with dough, the LPS group treated with dough plus LPS, and the LPS+MR-7 (LMR) group treated with dough plus LPS and MR-7. These three groups with 24 fish each were force-fed with 1 g dough daily for 7 continuous days. The results revealed that MR-7 administration ameliorated LPS-induced intestinal injury, showing higher intestinal villus and microvillus height. Further results showed that MR-7 could inhibit LPS-induced activation of TLR-NF-κB signaling thus maintaining the normal expression levels of cytokines and finally ameliorate the intestinal inflammatory response in turbot. Compared with the LPS group, LMR group had less goblet cells and lower mucin-2 expression level. Moreover, MR-7 restored LPS-induced down-regulation of tight junction protein-related gene expression (zonula occluden-1, occludin, tricellulin and claudin-3). Further investigations indicated that MR-7 partially counteracted LPS-induced changes in gut microbiota composition, enhanced the beneficial bacteria Lactobacillus and reduced the Pseudomonas, thus maintaining the overall microbiota balance. Taken together, the administration of MR-7 could effectively restore LPS-induced intestine function disorder in turbot by ameliorating inflammatory response, mucosal barrier dysfunction and microbiota dysbiosis.

2003-07-01·Journal of agricultural and food chemistry1区 · 农林科学

Ovipositional Responses of Chilo partellus (Swinhoe) (Lepidoptera: Pyralidae) to Natural Products from Leaves of Two Maize (Zea mays L.) Cultivars

1区 · 农林科学

Article

作者: Agarwal, Hari C. ; Jain, Subhash C. ; Singh, Ashok K. ; Babu, B. Ravindra ; Varshney, Anupam K.

Ovipositional responses of Chilo partellus (Swinhoe) (Lepidoptera: Pyralidae) to hexane extracts of leaves of two maize (Zea mays L.) cultivars, one resistant (Kisan) and one susceptible (Basilocal), were studied in two-choice bioassays. Gravid females laid a significantly higher percentage of eggs on substrates smeared with extract of Basilocal leaves (HEBL) (69%) than on those smeared with extracts of Kisan leaves (HEKL) (31%). Several chemicals were isolated from HEKL, three of which were characterized as dotriacontanol, heptadecanol, and nonadecanol. These chemicals were either absent or were present in very small amounts in HEBL, but in HEKL they were detected in much larger amounts. Each isolated chemical was tested for its effect on C. partellus oviposition in two-choice bioassays. Maximum ovipositional deterrence (90%) was observed for the compound MR-22a, followed in decreasing order by nonadecanol, MR-7, and heptadecanol. The identity of the remaining compounds is being investigated. The results indicate that the relative resistance of Kisan maize compared to Basilocal is partly due to the presence of certain ovipositional deterrents in its leaves.

2001-10-01·JOURNAL OF NUCLEAR MEDICINE

Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.

Article

作者: Waldmann, T A ; Carrasquillo, J A ; Yao, Z ; Eckelman, W C ; Garmestani, K ; Paik, C H ; Dadachova, E ; Wong, K J ; Yordanov, A ; Park, L S

METHODS:

In this study, we attached various radionuclides that result in alpha-emissions to T101, a rapidly internalizing anti-CD5 mAb. We then evaluated the catabolism and cellular retention and compared them with those of (125)I- and (111)In-labeled T101. T101 was labeled with (211)At, (125)I, (205,6)Bi, (111)In, and (203)Pb. CD5 antigen-positive cells, peripheral blood mononuclear cells (PBMNC), and MOLT-4 leukemia cells were used. The labeled T101 was incubated with the cells for 1 h at 4 degrees C for surface labeling. Unbound activity was removed and 1 mL medium added. The cells were then incubated at 37 degrees C for 0, 1, 2, 4, 8, and 24 h. The activity on the cell surface that internalized and the activity on the cell surface remaining in the supernatant were determined. The protein in the supernatant was further precipitated by methanol for determining protein-bound and non-protein-bound radioactivity. Sites of internal cellular localization of radioactivity were determined by Percoll gradient centrifugation.

RESULTS:

All radiolabeled antibodies bound to the cells were internalized rapidly. After internalization, (205,6)Bi, (203)Pb, and (111)In radiolabels were retained in the cell, with little decrease of cell-associated radioactivity. However, (211)At and (125)I were released from cells rapidly ((211)At < (125)I) and most of the radioactivity in the supernatant was in a non-protein-bound form. Intracellular distribution of radioactivity revealed a transit of the radiolabel from the cell surface to the lysosome. The catabolism patterns of MOLT-4 cells and PBMNC were similar.

CONCLUSION:

(211)At catabolism and release from cells were somewhat similar to that of (125)I, whereas (205,6)Bi and (203)Pb showed prolonged cell retention similar to that of (111)In. These catabolism differences may be important in the selection of alpha-radionuclides for radioimmunotherapy.

项与 iDD-003 相关的新闻（医药）

2025-12-16

·EINPresswire

StuffbyNainax LLC Issues Voluntary Nationwide Recall of MR.7 SUPER 700000 Dietary Supplement Due to the Presence of Undeclared Sildenafil and Tadalafil

COMPANY ANNOUNCEMENT When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement View Product Photos Summary Company Announcement Date: December 15, 2025 FDA Publish Date: December 16, 2025 Product Type: Dietary Supplements Drugs Reason for Announcement: Recall Reason Description Undeclared Sildenafil and Tadalafil Company Name: StuffbyNainax LLC Brand Name: Brand Name(s) Product Description: Product Description Dietary supplement for male enhancement Company Announcement Huntsville, Texas — StuffbyNainax LLC is voluntarily recalling all lots of MR.7 SUPER 700000 capsules to the consumer level. FDA analysis has found the product to be tainted with sildenafil and tadalafil, which are active ingredients in FDA-approved prescription drugs used to treat male erectile dysfunction and belong to a class of drugs known as phosphodiesterase type‑5 (PDE‑5) inhibitors. Products containing sildenafil or tadalafil cannot be marketed as dietary supplements. MR.7 SUPER 700000 capsules are considered an unapproved new drug for which safety and efficacy have not been established and are therefore subject to recall. Risk Statement: Consumption of products containing undeclared sildenafil or tadalafil may cause serious health risks. These ingredients may interact with nitrates found in certain prescription medications (such as nitroglycerin) and may result in a dangerous drop in blood pressure, which can be life‑threatening. Individuals with diabetes, high blood pressure, high cholesterol, or heart disease frequently take nitrates. Adult males who use nitrates for cardiac conditions are at the greatest risk. Product Description: The tainted MR.7 SUPER 700000 capsules are marketed as a dietary supplement for male enhancement. The affected product does not have lot numbers or expiration dates. The product was distributed nationwide in the United States to a limited number of online customers between August 2025 and November 2025. Affected Product: Product Name: MR.7 SUPER 700000 Brand: MR.7 Form: Capsules Lot Number: Not available / unlisted Distribution Period: August 2025 – November 2025 Distribution: Sold online in the United States This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 项与 iDD-003 相关的药物交易

登录后查看更多信息